29 reports of this reaction
3.2% of all BUTENAFINE HYDROCHLORIDE reports
#6 most reported adverse reaction
CONDITION AGGRAVATED is the #6 most commonly reported adverse reaction for BUTENAFINE HYDROCHLORIDE, manufactured by Bayer Healthcare LLC.. There are 29 FDA adverse event reports linking BUTENAFINE HYDROCHLORIDE to CONDITION AGGRAVATED. This represents approximately 3.2% of all 901 adverse event reports for this drug.
Patients taking BUTENAFINE HYDROCHLORIDE who experience condition aggravated should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONDITION AGGRAVATED is moderately reported among BUTENAFINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to condition aggravated, the following adverse reactions have been reported for BUTENAFINE HYDROCHLORIDE:
The following drugs have also been linked to condition aggravated in FDA adverse event reports:
CONDITION AGGRAVATED has been reported as an adverse event in 29 FDA reports for BUTENAFINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONDITION AGGRAVATED accounts for approximately 3.2% of all adverse event reports for BUTENAFINE HYDROCHLORIDE, making it a notable side effect.
If you experience condition aggravated while taking BUTENAFINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.